Johnson & Johnson (JNJ)
Johnson & Johnson Tops Q4 EPS Forecasts
Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago.
J&J CFO Joe Wolk: Anticipating 3% operational growth in 2025 despite 'significant' headwinds
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, slowdown in China, health care landscape in 2025, impact of the second Trump administration, and more.
J&J's stock surrenders early gains as weak sales guidance offsets earnings beat
Medtech and drug company's 2025 sales guidance is below consensus
J&J beats quarterly sales and profit estimates on cancer drug sales
Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson JNJ will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025.
Q4 Earnings: 3 Consumer Staples Titans on Deck
Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours.
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato, to treat adults with major depressive disorder, the company said on Tuesday.
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.
What Analysts Think of Johnson & Johnson Stock Ahead of Earnings
Johnson & Johnson (JNJ) is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from the same time last year.
